# wombat urls ß PLOS Medicine: A Peer-Reviewed Open-Access Journal
Advertisement
Research Article

Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient

  • Ninette Amariglio,

    Affiliations: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel, Institute of Hematology, Sheba Medical Center, Tel Hashomer, Israel

    X
  • Abraham Hirshberg,

    Affiliation: Department of Oral Pathology, School of Dental Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Bernd W Scheithauer,

    Affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America

    X
  • Yoram Cohen,

    Affiliation: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Ron Loewenthal,

    Affiliation: Tissue Typing Laboratory, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Luba Trakhtenbrot,

    Affiliation: Institute of Hematology, Sheba Medical Center, Tel Hashomer, Israel

    X
  • Nurit Paz,

    Affiliation: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Maya Koren-Michowitz,

    Affiliation: Institute of Hematology, Sheba Medical Center, Tel Hashomer, Israel

    X
  • Dalia Waldman,

    Affiliation: Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Leonor Leider-Trejo,

    Affiliation: Institute of Pathology, Tel-Aviv Medical Center, Tel-Aviv, Israel

    X
  • Amos Toren,

    Affiliation: Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Shlomi Constantini,

    Affiliation: Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Gideon Rechavi mail

    To whom correspondence should be addressed. E-mail: gidi.rechavi@sheba.health.gov.il

    Affiliations: Cancer Research Center, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel, Department of Pediatric Hemato-Oncology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel

    X
  • Published: February 17, 2009
  • DOI: 10.1371/journal.pmed.1000029

Reader Comments (11)

Post a new comment on this article

An Early Warning for Under-Estimated Risk of Cell Therapy

Posted by plosmedicine on 31 Mar 2009 at 00:34 GMT

Author: Shi Liu
Position: Scientist
Institution: Eagle Institute of Molecular Medicine, 1101 Overcliff Drive, Apex, North Carolina, 27502 USA
E-mail: SVL8EPA@gmail.com
Submitted Date: February 23, 2009
Published Date: March 2, 2009
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

Stem cell researchers should pay close attention to this incidence and really carefully re-assess the risks associated with their planned cell therapy.
If a "normal" stem cell could "mis-develope" into a tumor, then the likelihood of oncogene-induced and virus-integrated iPS cells would be more likely to contribute to tumor formation in human if put into clinic trials. Already all iPS cells have shown tumor formation in animals. However, some iPS cell researchers would even characterize these cells as "cancer-free" "safe" iPS cells. Amazing. See more detalied at http://im1.biz/Cloning.ht... .

Competing interests declared: I am an off-career-duty professionally-educated and hands-on trained life scientist (http://im1.biz/Liu_Discovery_English.htm). I am CEO of Truthfinding Cyberpress and editor-in-chief of its journals such as Logical Biology, Pioneer, Scientific Ethics, Top Watch, and International Medicine (http://im1.biz ) . I am the director of my life-time self-supporting research institute The Eagle Institute of Molecular Medicine. However, I have no financial interest in writing this response. The only competition is to compare my unique view on stem cells (http://im1.biz/StemCell.htm ) and their intrinsic aging (http://im1.biz/Aging.htm ) with mainstream views and to introduce my perspective on cloning (http://im1.biz/Cloning.htm ). But that was all aimed at increasing scientific understanding of the issues.